What is the revenue and EPS growth rate for SWK Holdings year over year?

Did SWK Holdings beat or miss consensus estimates last quarter?

What factors drove the changes in SWK Holdings's revenue and profit?

What is the market's earnings forecast for SWK Holdings next quarter?

What is SWK Holdings's gross profit margin?

What is SWK Holdings's latest dividend and current dividend yield?

What does SWK Holdings do and what are its main business segments?

What guidance did SWK Holdings's management provide for the next earnings period?

- **Capital Return Focus**: Returned $52 million to shareholders via dividend and buybacks, simplifying the business to focus on high-yield loans.
- **Stable Financial Performance**: Q2 non-GAAP net income of $4.6 million reflects reduced expenses (46% YoY decline) and stable loan book.
- **Disciplined Market Approach**: Avoiding excessive risk in competitive private credit market, with cautious capital deployment.

**【CEO Summary Section】**
- Completed sale of majority royalty assets and MOD3 subsidiary for approximately book value, returning $49 million to shareholders via a $4 per share dividend and $3 million through share buybacks.
- Remaining assets include $234 million in performing loans (14.1% yield), nonperforming reorg royalties, and private warrants; GAAP book value per share is $20.23, up 11.7% year-over-year after dividend.
- Q2 non-GAAP adjusted net income of $4.6 million, with a stated run rate expectation for future quarters.
- Sold MOD3 assets to Aptar for $6.9 million, with no recurring costs post-transition services agreement (ending mid-September).

**【CFO Financial Commentary】**
- GAAP pretax net income of $4.6 million ($0.37 per share), driven by $1.2 million decrease in finance receivables revenue (due to asset sales and paydowns) and $500,000 increase in pharmaceutical segment revenue.
- Operating expenses decreased 46% year-over-year to $5.4 million, with finance segment expenses down 43% to $4.2 million (driven by $3.3 million reduction in credit loss provisions).
- Repurchased 68,000 shares for $1.3 million during and after Q2, maintaining disciplined capital allocation.

**【Q&A Key Highlights】**
- **MOD3 Transition Costs**: No recurring costs post-sale; third-quarter noise from transition services agreement will be reimbursed, with ongoing SG&A expected to stabilize at ~$2 million.
- **FDA Regulatory Impact**: Minimal portfolio exposure; specialty pharma borrowers (e.g., rare disease, cash-pay dermatology) have limited pricing risk; one CDMO sees minor impact from NIH funding cuts.
- **Private Credit Market Competition**: Maintaining disciplined deployment; added to existing borrowers and made one new loan, avoiding excessive risk in a crowded market.

SWK Holdings Corporation (SWKH) Q2 2025 Earnings Call Transcript

- **Tangible Book Growth**: 10.5% YoY to $21.73/share, driven by finance segment and MOD3 Pharma contributions.
- **Portfolio Yield**: 14.5% modeled yield on $220M performing loans, targeting $32M annual interest income.
- **Share Buybacks & Dividends**: $1.1M repurchased YTD; $4/share special dividend declared, reducing book value to $18.11.
- **Credit Quality**: All-time high portfolio score (5/5), with 2-rated loans actively managed.
- **Capital Strategy**: Prioritize buybacks, dividends, and selective lending in $10-25M sweet spot.

**【CEO Key Highlights】**
- **Finance Segment Performance**: Q1 2025 adjusted non-GAAP net income of $8.6 million, trailing 12-month total of $26 million. Tangible book value per share grew 10.5% YoY to $21.73, with $0.38 contribution from MOD3 Pharma, totaling $22.11.
- **Royalty Portfolio Monetization**: Sold majority of royalty portfolio, reducing nonaccruals to $13 million (from $20 million). Current Finance Receivables portfolio yield 14.5%, targeting $32 million annual interest income.
- **Share Repurchases & Dividends**: Repurchased $1.1 million shares YTD; Board expects new repurchase program. Special $4/share dividend declared, reducing tangible book value to $18.11 post-payment.
- **Credit Portfolio Quality**: Portfolio ranked at 5 (highest score), with $220 million performing first lien loans. Two 2-rated loans ($20 million) remain accrual, with active borrower engagement.

**【CFO Financial Breakdown】**
- **GAAP Results**: Q1 2025 pretax net income $5.8 million ($0.48/share), down 30% YoY due to $2.4 million interest/fee decline offset by $2.1 million new funding.
- **Cost Efficiency**: Operating expenses decreased 64% YoY to $3.7 million, driven by 87% reduction in credit loss provisions ($6.8 million decline).
- **Liquidity**: $22 million gross cash, undrawn revolver. Pro forma Finance Receivables at $224 million post-royalty sale.

**【Q&A Key Takeaways】**
- **Capital Allocation Priorities**: 1) Stock buybacks (shares trading below book value), 2) Special dividends, 3) Selective new loans in $10-25M sweet spot.
- **Market Dynamics**: Neutral pipeline despite modest tightening in private credit market. Focus on sub-40% LTV loans with strong covenants.
- **Contingent Assets**: 12 zero-marked warrants/IP rights (e.g., MolecuLight, Zevra) with potential upside, though unpredictable.
- **Regulatory Risks**: No material impact from healthcare/regulatory changes on portfolio quality.


SWK Holdings Corporation (SWKH) Q1 2025 Earnings Call Transcript

- **Portfolio monetization success**: $51.3M total proceeds from royalty exits (45% IRR+, 2.7x+ MOIC)
- **Balance sheet strength**: $70M+ cash post-royalty sale, no revolver borrowings
- **Dividend signal**: Special dividend likely, recurring dividend under consideration
- **Buyback activity**: 100,000+ shares repurchased ($1.6M) at 20% discount to book
- **2025 growth drivers**: $218M performing loan portfolio yielding 15.5%, MOD3 CDMO scaling

**【CEO Opening Remarks】**
- Q4 2024 finance segment net income: $8.2 million
- $44 million capital deployed into life science receivables
- 8% YoY increase in non-GAAP tangible book value to $21.15
- 100,000 shares repurchased ($1.6 million) since Q3
- Key portfolio exits:
  - Veru royalty: 45% IRR, 2.7x MOIC
  - MolecuLight loan: 20% IRR, 1.6x MOIC
  - ANI Pharma royalty buyout: 20% IRR, 1.8x MOIC
- $34 million sale of remaining royalty portfolio (closing in ~2 weeks)
- Pro forma 2025 portfolio: $218M performing loans, $14M non-accruals, $5M equities
- 15.5% portfolio effective yield
- $30M+ cash on hand (pre-royalty sale)

**【CFO Financial Details】**
- GAAP net income: $5.9M (Q4 2024)
- Finance Receivables segment revenue +$1.1M vs. Q4 2023
- Operating expenses: $6.6M (flat vs. Q4 2023)
- MOD3 Pharma revenue: $3.6M (2024) vs. $1.2M (2023)
- 8.3% YoY increase in non-GAAP tangible book value
- $800K shares repurchased during Q4
- MOD3 transitioned to held-for-sale status

**【Q&A Highlights】**
- Dividend policy: Likely one-time special dividend post-royalty sale
- Share buyback: Active program with $1.6M repurchased since Q3
- 20% discount to book value viewed as attractive buyback trigger
- 2025 capital allocation focus: Portfolio yield maintenance, dividend consideration

SWKH

SWKH fundamentals

Earnings Call

You can ask Aime